Migraine.

@article{Ashina2020Migraine,
  title={Migraine.},
  author={Messoud Ashina},
  journal={The New England journal of medicine},
  year={2020},
  volume={383 19},
  pages={
          1866-1876
        }
}
  • M. Ashina
  • Published 5 November 2020
  • Medicine
  • The New England journal of medicine
A Bidirectional View of Migraine and Diet Relationship
  • P. Gazerani
  • Medicine
  • Neuropsychiatric disease and treatment
  • 2021
TLDR
A targeted review presents examples from current literature on the effects of diet on migraine features and effects of migraine on dietary choices to draw a perspective for future studies. Expand
Calcitonin gene-related peptide receptor antagonist ubrogepant for the treatment of acute migraine
TLDR
The meta-analysis showed that at 2 hours postdose, the percentages of participants reporting pain relief and the absence of photophobia, nausea, and phonophobia were significantly higher in the ubrogepant group than in the placebo group. Expand
Diagnosis and management of migraine in ten steps
TLDR
An expert panel provides recommendations for the diagnosis and management of migraine to support clinical decision-making by general practitioners, neurologists and headache specialists. Expand
Do anti-CGRP drugs have a role in migraine aura therapy?
TLDR
The patient suffered from chronic migraine with aura which was refractory to various pharmacological treatments, and was started an antiCGRP receptor monoclonal antibody therapy with erenumab (70 mg subcutaneously monthly), and both migraine and aura frequency dramatically dropped to maximum one attack per month, with persistent efficacy after one year. Expand
Editorial: Differences in Pain Biology, Perception, and Coping Strategies: Towards Sex and Gender Specific Treatments
TLDR
This paper aims to demonstrate the efforts towards in-situ applicability of EMMARM, as to provide real-time information about the effects of EMT on the immune system. Expand
Effect of Adrenomedullin on Migraine-Like Attacks in Patients With Migraine
TLDR
It is found that patients reported in a period of 0 to 12 hours stronger headache intensity after adrenomedullin compared to placebo infusion, which suggests that adrenomed Mullin or its receptors are novel therapeutic targets for the treatment of migraine. Expand
Effect of Vasoactive Intestinal Polypeptide on Development of Migraine Headaches
TLDR
A 2-hour infusion of VIP caused migraine attacks, suggesting an important role of VIP in migraine pathophysiology and its receptors could be potential targets for novel migraine drugs. Expand
Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial.
TLDR
Among patients eligible for preventive migraine therapy experiencing a moderate to severe migraine attack, treatment with intravenous eptinezumab vs placebo shortened time to headache and symptom resolution. Expand
Extreme ecchymoses in a migraine patient using concomitant treatment with calcitonin gene-related peptide receptor antibodies and fish oil supplements: a case report
TLDR
The first case of an increased tendency to bruise in a migraine patient treated with erenumab is reported, indicating that small and unnoticeable bruises may be aggravated instead in patients with tendency to Bruise caused by for instance fish oil supplements. Expand
Galcanezumab effectiveness on comorbid cluster headache and chronic migraine: a prospective case series
TLDR
Taking into account the role of C GRP in migraine and CH pathophysiology, a usually well-tolerated treatment with CGRP blockade could be a rationale-based option to treat patients with coexisting chronic migraine and cluster headache. Expand
...
1
2
3
4
...